ZYVERSA THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.38 million shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 16.38M shares, a 324.01% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 3.86M shares, a 450.50% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 701.90K shares, a 1925.52% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 34.65K shares.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.30M shares, a 315.12% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 1.76M shares, a 92.09% increase from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 915.66K shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 11 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 16.38M shares 10-Q · filed 2026-05-13 | ||||||||||
| 2025-12-31 | 7.30M shares 10-K · filed 2026-03-31 | ||||||||||
| 2025-09-30 | 7.30M shares 10-Q · filed 2025-11-19 | ||||||||||
| 2025-06-30 | 3.86M shares 10-Q · filed 2025-08-13 | ||||||||||
| 2025-03-31 | 3.86M shares 10-Q · filed 2026-05-13 | ||||||||||
| 2024-12-31 | 1.76M shares 10-K · filed 2026-03-31 | ||||||||||
| 2024-09-30 | 940.37K shares 10-Q · filed 2025-11-19 | ||||||||||
| 2024-06-30 | 701.10K shares 10-Q · filed 2025-08-13 | ||||||||||
| 2024-03-31 | 701.90K shares 10-Q · filed 2025-05-12 | ||||||||||
| 2023-12-31 | 915.66K shares 10-K · filed 2025-03-27 | 9.16M shares 10-K · filed 2024-03-25 | |||||||||
| 2023-09-30 | 116.24K shares 10-Q · filed 2024-11-14 | 40.68M shares 10-Q · filed 2023-11-14 | |||||||||
| 2023-06-30 | 80.43K shares 10-Q · filed 2024-08-09 | 28.12M shares 10-Q · filed 2023-08-21 | |||||||||
| 2023-03-31 | 34.65K shares 10-Q · filed 2024-05-15 | 12.10M shares 10-Q · filed 2023-05-12 | |||||||||
| 2022-12-31 | 342.62K shares 10-K · filed 2024-03-25 | 11.99M shares 10-K · filed 2023-03-31 | |||||||||
| 2022-12-12 | 25.01M shares 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |